Setback
Accuray spent $16.2 million on restructuring in its 2026 fiscal year.
A delay, pause or setback
What the source says
“Operating expenses in fiscal 2026 include $16.2 million of restructuring charges.”
What it means
CyberKnife, from Accuray, is at stage 5 of 5 on our ladder: regulator-cleared or mass market. A setback stays on the record next to the milestones; the stage moves down only when the rules say so.
Human help: Our sources report it working without human help.
More on CyberKnife
- Accuray's new product orders fell to $191.9 million in its 2026 fiscal year, from $288.0 million a year before. The figure covers all of Accuray's machines, not only CyberKnife.
- The FDA cleared a CyberKnife add-on through the 510(k) route that lets doctors treat lung tumors without first implanting small marker seeds.
- Accuray marked its 200th CyberKnife installation.
- The FDA cleared CyberKnife through the 510(k) route to treat tumors anywhere in the body where radiation is called for.
- The FDA cleared CyberKnife to treat tumors in the head and neck.